Traws Pharma 과거 수익 실적
과거 기준 확인 0/6
Traws Pharma's earnings have been declining at an average annual rate of -20.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 58.1% per year.
주요 정보
-20.4%
수익 성장률
79.9%
EPS 성장률
Pharmaceuticals 산업 성장 | 7.3% |
매출 성장률 | -58.1% |
자기자본 수익률 | -2,247.1% |
순이익 | -60,641.2% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
수익 및 비용 분석
Traws Pharma 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 0 | -137 | 10 | 11 |
31 Mar 24 | 0 | -18 | 10 | 9 |
31 Dec 23 | 0 | -19 | 9 | 11 |
30 Sep 23 | 0 | -20 | 9 | 13 |
30 Jun 23 | 0 | -21 | 8 | 14 |
31 Mar 23 | 0 | -21 | 8 | 13 |
31 Dec 22 | 0 | -19 | 8 | 11 |
30 Sep 22 | 0 | -17 | 9 | 9 |
30 Jun 22 | 0 | -15 | 9 | 8 |
31 Mar 22 | 0 | -16 | 9 | 7 |
31 Dec 21 | 0 | -16 | 9 | 7 |
30 Sep 21 | 0 | -19 | 9 | 10 |
30 Jun 21 | 0 | -22 | 9 | 13 |
31 Mar 21 | 0 | -25 | 9 | 15 |
31 Dec 20 | 0 | -25 | 8 | 17 |
30 Sep 20 | 0 | -24 | 8 | 16 |
30 Jun 20 | 0 | -23 | 8 | 16 |
31 Mar 20 | 2 | -19 | 7 | 15 |
31 Dec 19 | 2 | -22 | 7 | 15 |
30 Sep 19 | 2 | -21 | 7 | 16 |
30 Jun 19 | 2 | -22 | 7 | 16 |
31 Mar 19 | 1 | -23 | 7 | 16 |
31 Dec 18 | 1 | -21 | 8 | 17 |
30 Sep 18 | 1 | -21 | 7 | 17 |
30 Jun 18 | 1 | -23 | 7 | 18 |
31 Mar 18 | 1 | -21 | 7 | 19 |
31 Dec 17 | 1 | -24 | 7 | 19 |
30 Sep 17 | 1 | -23 | 8 | 21 |
30 Jun 17 | 2 | -18 | 9 | 19 |
31 Mar 17 | 4 | -21 | 8 | 19 |
31 Dec 16 | 6 | -20 | 9 | 20 |
30 Sep 16 | 15 | -11 | 8 | 19 |
30 Jun 16 | 15 | -15 | 8 | 20 |
31 Mar 16 | 13 | -19 | 10 | 22 |
31 Dec 15 | 11 | -24 | 10 | 26 |
30 Sep 15 | 2 | -41 | 11 | 32 |
30 Jun 15 | 0 | -50 | 12 | 38 |
31 Mar 15 | 0 | -57 | 13 | 45 |
31 Dec 14 | 1 | -64 | 15 | 49 |
30 Sep 14 | 3 | -65 | 16 | 51 |
30 Jun 14 | 4 | -71 | 19 | 55 |
31 Mar 14 | 4 | -68 | 18 | 52 |
31 Dec 13 | 5 | -65 | 17 | 50 |
양질의 수익: 0T20 is currently unprofitable.
이익 마진 증가: 0T20 is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 0T20 is unprofitable, and losses have increased over the past 5 years at a rate of 20.4% per year.
성장 가속화: Unable to compare 0T20's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: 0T20 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
자기자본 수익률
높은 ROE: 0T20 has a negative Return on Equity (-2247.07%), as it is currently unprofitable.